C oronary artery disease leads to compromised myocardial blood supply and the typical symptoms of stress-induced angina. Although pharmaceutical therapy and revascularization of stenotic epicardial coronary arteries are the standard therapy for coronary artery disease, many patients with advanced disease or small-vessel disease respond poorly to these treatments. Novel therapeutic strategies for promoting collateral artery formation, or arteriogenesis, are in high demand. 1, 2 Although vascular endothelial growth factor (VEGF) is the most potent angiogenic factor for possible therapy of myocardial ischemia, 3 it also promotes vascular leakage, inflammation, and the formation of angioma-like vascular structures, 4 -7 which has hampered its utility in therapeutic angiogenesis. Among the VEGF family members, placenta growth factor (PlGF) has shown the most promise for promoting therapeutic arteriogenesis in preclinical studies. 7
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VEGF-B, isolated in 1995, 8 has been an exceptional member of the VEGF family in that efforts to discover a blood vascular function for VEGF-B have had largely nega-tive results. 6 VEGF-B knockout (KO) mice are viable and display at most mild cardiac phenotypes such as a slightly smaller heart size in 1 genetic background or a mild delay in atrioventricular coupling in another strain. 9, 10 Transgenic (TG) or adenoviral overexpression of VEGF-B in the skin or skeletal muscle increased blood vessel density only minimally. 11, 12 Interestingly, however, strong overexpression of VEGF-B by adenoviral transduction induced heart-specific capillary dilation and increased collateral blood vessel growth after myocardial infarction in pigs. 13 VEGF-B is expressed as 2 RNA splice isoforms. 14 Recently, we demonstrated that when overexpressed in the mouse heart, the heparin-binding VEGF-B 167 isoform induced cardiac hypertrophy without overt angiogenesis, although it caused mild enlargement of myocardial blood capillaries. 12 The other isoform, VEGF-B 186 , is O-glycosylated, proteolytically processed, and freely diffusible. Both isoforms bind to and activate VEGF receptor-1 (VEGFR-1) and neuropilin-1. 15, 16 Several studies have indicated that the VEGF-B isoforms are expressed simultaneously in various tissues. 14 PlGF binds to the same receptors as VEGF-B and has been shown to promote angiogenesis and arteriogenesis in pathological conditions. 17 The aim of this study was to investigate the mechanisms of VEGF-B action in the heart in more depth. A critical question about the effects of VEGF-B in the myocardium is how they differ from those of PlGF and whether VEGF-B could provide a means to improve myocardial function in the failing heart. Because adenoviral transduction in an immunocompetent host is short-lived and results in nonspecific inflammation, we have instead used adenoassociated viral and TG delivery of VEGF-B to the mouse and rat heart.
Methods
A detailed description of the methods used is provided in the online-only Data Supplement.
Construction and Preparation of the Recombinant Adeno-Associated Virus Vectors
Mouse VEGF 120 , PlGF, VEGF-B 167 , VEGF-B 186 , and human serum albumin complementary DNAs were cloned into the psubCMV-WPRE recombinant adeno-associated virus (AAV) expression vector. AAV particles were injected into tibialis anterior muscles or the left ventricle.
Generation of ␣MHC-VEGF-B TG Mice and Rats
A fragment of the human VEGF-B gene and the mouse VEGF-B Ex1-5 fragment were isolated and cloned into the ␣-myosin heavy chain (␣MHC) promoter expression vector (a kind gift from Dr Jeffrey Robbins). TG animals were generated by microinjection of fertilized oocytes from FVB/N mice or HsdBrl:WH Wistar rats. All animal experiments were approved by the Provincial State Office of Southern Finland and carried out in accordance with institutional guidelines.
Immunohistochemistry, Microscopy, and Image Analysis
The antibodies and methods used are detailed in the online-only Data Supplement. 
Blood Pressure Measurements and Echocardiography

Micro-Computed Tomography Imaging of the Cardiac Vessels
Coronary angiographies were performed with the Inveon microcomputed tomography scanner (Siemens, Knoxville, Tenn). The ascending aorta was cannulated and clamped, and iodinated intravascular contrast agent eXIATM160XL (Binitio Biomedical Inc, Ottawa, Ontario, Canada) was carefully injected manually to fill the cardiac blood vessels, avoiding very high pressure.
Assessment of Myocardial Perfusion, Oxygen Consumption, and Efficiency of Work
Eight rats were given a slow bolus of 30Ϯ24 MBq of [ 11 C]acetate and imaged with the Inveon micro-positron emission tomography scanner (Siemens, Knoxville, Tenn).
Statistical Analysis
Values are presented as meanϮSD unless otherwise indicated. Statistical analysis was performed with 1-way ANOVA (posthoc with Tukey test) or with the 2-tailed unpaired Student t test unless otherwise specified in the Results. Differences were considered statistically significant at PϽ0.05.
Results
Unlike PlGF, VEGF-B Fails to Induce Capillary Angiogenesis or Arteriogenesis in Mouse Skeletal or Cardiac Muscle
To compare the effects of VEGF-B and PlGF, which bind to VEGFR-1 and neuropilin-1, we injected recombinant AAVs encoding VEGF-B 167 , VEGF-B 186 , and PlGF, as well as VEGF and human serum albumin as positive and negative controls, respectively, into mouse tibialis anterior muscles. Immunofluorescence staining of the muscles for platelet endothelial cell adhesion molecule (PECAM)-1 and ␣-smooth muscle actin (SMA) 4 weeks after injection indicated strong capillary angiogenesis with primarily smooth muscle cell-coated vessels in PlGF-injected muscles, whereas no evidence of angiogenesis was seen in muscles overexpressing either VEGF-B isoform (Figure 1 ). In the VEGF-injected muscles, endothelial cell proliferation resembled angioma formation ( Figure 1 ). As expected on the basis of prior work with adenoviral vectors, PlGF and VEGF increased blood perfusion in the muscles, whereas even a combination of VEGF-B 167 and VEGF-B 186 had no effect on perfusion ( Figure IA in the online-only Data Supplement). Interestingly, Evans Blue dye injection experiments indicated that although PlGF and VEGF increased vascular permeability, VEGF-B 167 and VEGF-B 186 did not ( Figure IB in the online-only Data Supplement). Similar effects were obtained when the same AAV vectors were expressed in the myocardium ( Figure II in the online-only Data Supplement). Importantly, mice injected with PlGF or VEGF vectors had to be euthanized within 2 weeks because of edema, whereas the VEGF-B-expressing mice showed no signs of distress (data not shown).
VEGF-B, in Contrast to PlGF, Does Not Induce Inflammation in Skeletal or Cardiac Muscle
Immunofluorescence staining of sections from mouse skeletal muscles transduced with the AAVs encoding PlGF or VEGF revealed marked infiltration of CD45-positive leukocytes and especially F4/80-positive macrophages. In contrast, overexpression of either VEGF-B isoform could at best only mildly increase macrophage infiltration ( Figure IIIA 
Both Mice and Rats Overexpressing the Human VEGF-B Gene in the Myocardium Exhibit Cardiac Hypertrophy
To test the therapeutic potential of VEGF-B both in mice and in a larger animal model, we adopted a gain-of-function approach. Because several studies have indicated that both VEGF-B isoforms are simultaneously expressed, 14 we overexpressed the full-length human VEGF-B gene under the ␣MHC promoter in mice and rats. The schematic structure of the transgene is shown in Figure IVA in the online-only Data Supplement. Analysis of the TG mice and rats at 3 to 6 months of age indicated robust transgene expression in Western blot analysis of the heart lysates ( Figure IVC in the online-only Data Supplement and data not shown). As can be seen from that figure, all 5 TG rat founder hearts contained both full-length and processed VEGF-B 186 polypeptides (32 and 14 kDa, respectively), as well as VEGF-B 167 polypeptides (22 kDa). Immunofluorescence staining for VEGF-B in the rat hearts demonstrated a mosaic pattern of expression in the cardiomyocytes (TG2), except for the highest expressing founder (TG3), which showed staining in all cardiomyocytes ( Figure IVE in the online-only Data Supplement). Three of these founder lines (TG2 through TG4) were used in subsequent experiments with essentially similar results.
Both the TG mice and rats developed cardiac hypertrophy, with an increased ratio of heart to body weight and cardiomyocyte size as determined by staining of the cardiomyocyte plasma membrane with anti-dystrophin antibodies at 4 to 5 months of age (Figure 2A through 2C). Echocardiographic analysis of the TG rat hearts revealed a significantly increased left ventricular wall thickness at 5 months of age ( Figure 2D and the Table) , which was associated with a decrease in end-systolic volume (the Table) . Interestingly, however, the TG rats maintained heart function, as shown by analysis of the ejection fraction and fractional shortening (the Table) . In addition, the TG rats tended to have lower blood pressure and heart rate than wild-type (WT) controls ( Figure  2E and the Table) . No degenerative changes comparable to those seen previously in ␣MHC-VEGF-B 167 mouse hearts 12 were seen in the rat cardiomyocytes at 4 months of age in electron microscopy or in older rats, whereas cardiomyocyte damage and fibrosis were evident in light microscopy of 1-year-old ␣MHC-VEGF-B mice ( Figure V in the onlineonly Data Supplement and data not shown).
The VEGF-B Transgene Induces Strong Coronary Arteriogenesis in Rats
A striking observation made in the analysis of histochemically stained sections of TG rat, but not mouse, hearts was the presence of numerous large arteries of nearly the caliber of epicardial coronary arteries ( Figure 3A and 3D, arrowheads). They were located deep in the myocardium and often close to the endocardium, whereas similarly sized arteries were seen only on the epicardial side in WT hearts ( Figure 3D , arrow). The total number of arteries as analyzed by Masson trichrome staining for the adventitial layer was significantly increased in TG heart sections at 4 months of age, especially in the subendocardial myocardium ( Figure 3A through 3D ). The number of arteries in TG rat hearts was significantly increased also at 6 to 8 weeks of age (83Ϯ14 total arteries per heart section in ␣MHC-VEGF-B rat hearts versus 60Ϯ2 arteries per heart section in WT hearts; nϭ6 in both groups; PϽ0.005). The average arterial vessel area was significantly increased in the TG heart sections ( Figure 3C ), and the arterial phenotype was also associated with dilation of the epicardial veins ( Figure 3A , arrows). Consistent with the arteriogenesis, VEGF-B induced a number of cytokines that have been associated with angiogenesis and tissue remodeling. Notably, VEGF-B increased the expression of the delta-like 4 (Dll4) notch ligand, which has been associated with arteriogenesis 18 ( Figure VI in the online-only Data Supplement). We also saw the induction of plasminogen activator inhibitor (PAI)-1, which is involved in matrix remodeling and, for example, myoendothelial junction formation. 19 Immunostaining re-vealed that PAI-1 was expressed mainly in the arterial walls ( Figure 4C ). Resorcin Fuchsin staining for elastin indicated that most of the smooth muscle cell proliferation had occurred in the media of the arteries of 1-month-old VEGF-B TG hearts, whereas some fragmentation of the internal elastic lamina was seen in many of the arteries from 4-month-old TG rats ( Figure 3E , white arrowheads). In line with the results from the AAV-transfected mice, immunostaining with antibodies against the macrophage marker ED-1 did not indicate significant inflammatory cell infiltration (39Ϯ14 cells in ␣MHC-VEGF-B versus 36Ϯ9 cells in WT heart sections; PϾ0.05, nϭ5 in both groups). No increase in fibrosis could be seen in Masson trichrome staining of the hearts at 1 or 4 months ( Figure 3D and data not shown).
Immunofluorescent SMA staining confirmed the presence of a thick periendothelial smooth muscle cell layer in the TG arteries ( Figure 4A and B) . In contrast, staining for the rat endothelial cell antigen RECA-1 did not reveal increased blood capillary density (immunostained area, 11.7Ϯ2.2% in TG [nϭ4] versus 11.8Ϯ4.9% in WT hearts [nϭ5]; PϾ0.05). However, similar to previous observations in TG mice, 12 we could observe some increase in mean capillary vessel luminal areas (data not shown).
To analyze whether the myocardial arteries in the TG hearts were functional and connected to the coronary arterial tree, we performed contrast-enhanced micro-computed tomography angiography of the rat hearts. The coronary arteries and veins and the epicardial vessels were found in anatomically normal locations, but remarkably, the number and size of coronary vessel branches were strikingly increased in TG hearts compared with controls ( Figure 5, arrows) , with large vessels also seen deep inside the myocardium (Figure 5 , arrowhead, and data not shown). In vivo positron emission tomography showed homogeneous uptake of [ 11 C]acetate throughout the left ventricular myocardium of the rats. The average myocardial perfusion was comparable in the TG and 
Neuropilin-1 Does Not Transduce VEGF-B Signals Essential for the Hypertrophic Response
To establish the VEGF-B signal transduction pathway involved in the hypertrophy response, we first concentrated on the 2 receptors of VEGF-B in mice. A C-terminally truncated form of VEGF-B containing the first 5 exons and thus lacking the isoform-specific sequences and therefore also the neuropilin-1-and heparin-binding domain 15 was expressed in mouse heart (␣MHC-VEGF-B Ex1-5 ; Figure IVB and IV in the online-only Data Supplement). Analysis of the TG hearts indicated that they undergo a degree of hypertrophy similar to that of hearts overexpressing the full-length gene or the VEGF-B 167 form (PϽ0.05, Mann-Whitney U test; Figure  2F ). This indicated that, despite its expression at least in fetal myocardium, 15 neuropilin-1 binding does not mediate the hypertrophic response.
Deletion of the VEGFR-1 Tyrosine Kinase Domain Attenuates the Hypertrophic Effect of VEGF-B
To analyze the role of VEGFR-1 signal transduction in the VEGF-B-induced cardiac hypertrophy, we mated the ␣MHC-VEGF-B 167 TG mice with mice having a deletion of the VEGFR-1 tyrosine kinase domain (VEGFR-1 TKϪ/Ϫ) but no obvious phenotype. 20 Analysis of offspring 3 to 4 months after birth revealed that cardiac overexpression of VEGF-B had no effect on ratios of heart to body weight in VEGFR- 
Loss of Bmx Reduces VEGF-B-Induced Cardiac Hypertrophy
The cytoplasmic bone marrow kinase in chromosome X (Bmx) is expressed in the arterial endothelium and myeloid cell lineage; its deletion from mice does not lead to any apparent phenotype, 21 but interestingly protects mice from cardiac hypertrophy induced by aortic constriction. 22 To evaluate whether Bmx deficiency inhibits the VEGF-Binduced hypertrophy, we crossed Bmx gene-targeted mice with the ␣MHC-VEGF-B 167 mice. We then compared mice of 4 genetic backgrounds: ␣MHC-VEGF-B 167 , ␣MHC-VEGF-B 167 ;Bmx-/0, WT, and Bmx-/0 (KO) mice. At the age of 3 to 3.5 months, when the hypertrophic phenotype of ␣MHC-VEGF-B 167 mice is apparent, 12 the mice were euthanized and the heart tissues analyzed. Loss of Bmx attenuated the cardiac hypertrophy induced by VEGF-B ( Figure 6A and  6C ). In addition, the average cardiomyocyte area was significantly reduced in the ␣MHC-VEGF-B 167 ;Bmx KO hearts compared with the ␣MHC-VEGF-B 167 hearts ( Figure 6B and  6D) . These results indicate that Bmx mediates at least some of the signals for the VEGF-B-induced hypertrophy via the arterial endothelium. 
Discussion
In the present study, we show that VEGF-B induces a striking growth of the coronary vascular tree in the rat, but not mouse, heart and promotes myocardial hypertrophy in both species. Importantly, VEGF-B, unlike PlGF or VEGF, did not significantly increase vascular permeability or inflammatory cell recruitment into cardiac or skeletal muscle. The VEGF-Binduced hypertrophy did not compromise myocardial contractile function at least in rats up to 5 months of age, and the impressive arteriogenesis was not associated with intimal thickening, although the internal elastic lamina of the arteries had undergone some pathological changes in older rats. It has previously been shown that myocardial hypertrophy in the absence of other stimuli can be induced by angiogenesis in mice. 23 Heart-specific overexpression of both VEGF-B isoforms in mice and rats reproduced the hypertrophic phenotype previously seen in ␣MHC-VEGF-B 167 mice. 12 Both the TG mice and rats had significantly increased ratios of heart to body weight and hypertrophy of the cardiomyocytes. Even though increases in capillary density were not observed in the TG animals, it is conceivable that endothelium-derived functions activated by VEGF-B mediate the cardiac hypertrophy. Echocardiography confirmed the increased left ventricular mass in the TG rats and, similar to our previous analysis of mice, showed that despite circumferential hypertrophy, VEGF-B overexpression did not compromise systolic function. Indeed, VEGFR-1 activation by VEGF-B has been found to elicit a gene expression profile typical of the compensatory, hypertrophic response both in cultured cardiomyocytes and in infarcted hearts. 24 In mice, the hypertrophy ultimately resulted in exhaustion of triglycerides and accumulation of toxic lipid species, resulting in mitochondrial autophagy/lysis and cardiomyopathy (Reference 12 and our unpublished observations). The cardiomyocytes in ␣MHC-VEGF-B rats, however, have not shown signs of lipotoxic damage, perhaps because of a preserved perfusion of the hypertrophic myocardium induced by the strong coronary arteriogenesis in this species. Importantly, functioning arteries are essential for the sufficient perfusion of tissues. 2 In contrast to VEGF-B, PlGF strongly increased vascular permeability. In addition, a novel snake venom VEGF has been shown to induce vascular permeability through preferential signaling via VEGFR-1. 25 Another major difference observed between VEGF-B and PlGF was the lack of inflammatory cell recruitment into skeletal or cardiac muscle by VEGF-B. In previous work, the recruitment of bone marrow-derived cells, mainly monocytes/macrophages, correlated with arteriogenesis, 2 and this required the neuropilin-1-binding domain of VEGF. 26 The hypertrophic effects of VEGF-B did not require activation of neuropilin-1; overexpression of a truncated form of VEGF-B capable of binding to VEGFR-1 but lacking the neuropilin-1-binding domain 15 induced significant cardiac hypertrophy. On the other hand, deletion of the VEGFR-1 tyrosine kinase domain in the VEGF-B TG mice inhibited hypertrophy induced by VEGF-B, indicating that VEGFR-1 signaling provides the major pathway. This finding is of interest because the VEGFR-1 tyrosine kinase function seems dispensable for normal vascular development. 27 Strikingly, in the TG rats but not in the mice, VEGF-B induced a remarkable growth of large arterial blood vessels that were found deep in the subendocardial myocardium, without causing capillary proliferation. These arteries were often larger than or equal in size to epicardial coronary arteries in control animals and were covered by a thick smooth muscle cell wall, with additional cell layers in the arterial media. Three-dimensional micro-computed tomography angiography suggested that the myocardial arteries formed part of an extended coronary arterial tree continuous with the epicardial coronary vessels, which in the TG hearts had larger and more numerous branches. The resting myocardial perfusion, oxygen consumption, and efficiency of work were preserved in the TG rats. Thus, VEGF-B induced a strong arteriogenic response in the coronary vessels, which was also associated with the upregulation of Dll4 in the TG rat hearts. Importantly, this occurred without capillary angiogenesis, vascular leakage, or inflammation. Increased PAI-1 protein was detected in the TG rat hearts, which likely resulted from the arterial growth because PAI-1 was expressed mainly in the arterial walls. A recent report has also indicated the importance of PAI-1 in myoendothelial junction formation. 19 Further studies in animals with atherosclerosis or myocardial infarction are needed to demonstrate the potential beneficial effects of arteriogenesis on myocardial function.
We do not yet know why the human VEGF-B gene induces coronary arteriogenesis in rat but not mouse hearts. However, it is interesting that the results we obtained in the rats are almost a mirror image of those reported by Bellomo et al 9 in the VEGF-B gene-targeted mice that developed slightly smaller hearts than wild-type mice during the first postnatal month. In vitro perfusion experiments of the VEGF-B gene-targeted mice indicated that their isolated hearts display vascular dysfunction after coronary occlusion and impaired recovery from experimentally induced myocardial ischemia. 9 This finding and our present data warrant detailed analysis of the arteriogenic potential of VEGF-B in the rat heart in utero, during early postnatal coronary maturation, and in the adult heart. It is also interesting to note that blockage of VEGFR-1 signal transduction by use of a soluble form of the receptor that captures VEGF, VEGF-B, and PlGF leads to myocardial stunning or hibernation, which has been described in chronic myocardial ischemia. 28 On the other hand, VEGF-B 167 was reported to exert a powerful antiapoptotic effect on cardiomyocytes both in cell culture and in vivo after myocardial infarction. 24 In addition, VEGF-B 167 was also shown to preserve cardiac function in dogs developing tachypacinginduced dilated cardiomyopathy and to prevent oxidative stress and loss of mitochondrial membrane potential in neonatal rat cardiomyocytes exposed to angiotensin II. 29 These results suggest important cardioprotective roles for VEGF-B in heart failure.
Recent reports indicate that pressure overload-induced cardiac hypertrophy generated by thoracic aortic constriction in mice is mediated at least in part through Bmx tyrosine kinase, which is expressed in the atrial endocardium and arterial endothelium. 21, 22 Furthermore, previous in vitro data from our laboratory show that Bmx phosphorylation can be stimulated by activated VEGFR-1, indicating a role in the downstream signaling of this receptor. 21 Here, we show that Bmx deletion also reduces the cardiac hypertrophy induced by VEGF-B overexpression. These results provide the first evidence for the interaction between the VEGF-B and Bmx signaling pathways in vivo. Interestingly, the rescue of the phenotype in the Bmx KO background implicates the arterial endothelium as an important source for the hypertrophic signals. However, further studies need to be performed to improve our understanding of the mechanisms involved.
The recent findings that VEGFR-1 activation by VEGF-B increases cardiac mass and promotes maintenance of cardiac contractility over time have obvious therapeutic implications. 12, 24, 29 Prolonged cardiac hypertrophy leads to diastolic insufficiency, whereas concurrent cardiac angiogenesis in such conditions has been shown to be important for preservation of cardiac function. 30, 31 VEGF-B may provide this essential function, as we demonstrate that overexpression of both isoforms of VEGF-B in the rat heart induces concurrent myocardial growth and growth of arteries that penetrate into the myocardium. Importantly, VEGF-B does not promote vascular leakage or tissue inflammation, both of which have in part compromised previous attempts to use growth factors of the VEGF family in therapeutic angiogenesis. Thus, VEGF-B seems to be a more promising therapeutic candidate than PlGF or VEGF for patients with myocardial ischemia.
